Followers | 1076 |
Posts | 80420 |
Boards Moderated | 5 |
Alias Born | 03/10/2009 |
Wednesday, May 13, 2020 7:46:46 AM
GlobeNewswire GlobeNewswire•April 22, 2020
NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNewsWire (NNW), discussed the Predictive Oncology’s distinctive business model and significant changes management is making to position the Company for the future.
The broadcast of the exclusive audio interview produced by NNW, a financial news and content distribution company and one of 40+ brands in the InvestorBrandNetwork (IBN), can be heard at nnw.fm/o7Ysq.
The interview discusses the evolution of Predictive Oncology. “As we moved forward, we changed our focus to artificial intelligence through our wholly owned subsidiary Helomics,” Schwartz said. Another key change came with the acquisition of a second wholly owned subsidiary, TumorGenesis. Continuing this growth strategy, the Company is now is in the process of acquiring two biological firms: Soluble Therapeutics and BioDtech.
“Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty. In fact, this is the largest inventory of its kind in the world,” stated Schwartz.
Schwartz further explained that this phenomenal collection was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. “The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor,” he said. “And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.”
The Company’s ultimate goal for Helomics is to replicate the path taken by Foundation Medicine and its relationship with Roche Pharmaceutical in obtaining funds for research.
“We ultimately need to prove that we’re able to sequence, which is genetically profile our tumors, and do what is called a ‘reach back,’ or examination of what eventually happened to these patients over an extended period of time,” Schwartz said. “I want to strongly emphasize that Helomics is the only company with the ability to do this ‘reach back’ at this time because only we have a patient history. I want to make sure I emphasize that we’re the only company that has this history.”
During the interview, Schwartz also pointed out other key components of Predictive Oncology’s strategic plan moving forward, including its CancerQuest 2020 project conducted in partnership with UPMC Magee, an agreement with Interface Diagnostics to do a thyroid study utilizing POAI’s AI model, and other projects involved precision medicine trials and prostate cancer.
“This should be enough information to demonstrate our ability to validate our process,” Schwartz said. “We will then go to pharma industry for major funding. And we’re pretty excited about this. We think we’re going to finally get to the top of the heap here very shortly.”
Listen to the full interview with Predictive Oncology’s Carl Schwartz at http://nnw.fm/o7Ysq
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent POAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 09:00:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:15 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/15/2024 09:16:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:01:03 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:00:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 12:00:20 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/21/2024 07:39:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:01:08 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:00:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:00:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/07/2023 01:54:30 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/05/2023 09:15:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 10:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:06:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:05:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:03:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:03:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 10:25:18 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM